Innate lymphoid cells (ILCs) are immune cells which appear morphologically as lymphoid cells but do not express specific antigen receptors (an essential feature of adaptive immune cells) encoded by rearranged genes (i.e. T-cell receptors (TCRs) expressed by T cells). By origin, these cells represent a heterogeneous group of hematopoietic innate immune cells. ILCs differentiate from common lymphoid progenitor (CLP) cells ( Fig. 1 ) and comprise a small fraction of the total immune cell population in different lymphoid organs, at mucosal epithelial barriers and in various other tissues. Moreover, these cells are capable of producing an array of effector cytokines which are similar to helper T-cell cytokines. Thus, these cells include a variety of cell types sharing common phenotypic and functional characters (1, 2) . However, mouse models of infection and inflammation play a very important role in identifying and classifying their phenotypic characters and their functional diversity (3) (4) (5) . A recent study identified that in mouse fetal liver and adult bone marrow cells expressing high levels of PLZF, transcription factors act as common precursors for ILCs and are known as ILCPs. These ILCPs are further differentiated into ILC 1, ILC2 and ILC3 cells, however, NK cells and LTi cells do not originate from these ILCPs (6) . Experts in this field have agreed that the term ILCs should be used to encompass the lineage marker-negative (LIN-) ILCs, .natural killer (NK) cells and lymphoid tissue-inducer (LTi) cells (7) . Therefore, it has been suggested that ILCs can be further divided into three major groups:
i. Group 1 ILCs (comprised ofILCl and Natural Killer (NK) cells), include IFN-y producing ILCs, expressing T-box transcription factor T-bet and/or Eomes;
ii. Group 2 ILCs (ILCs 2) are GATA-binding protein 3 (GATA3) and RORa-dependent ILCs, which require these transcription factors for their growth, development and function. These group 2 A novel population of intraepithelial group I ILCs has been reported, which are NKp44+CD I03+ cells and are characterized by the expression of CD160, NKp46 and NKl.l (8) . Significantly low number of these group I ILCs have been observed in mice lacking Nfi13 (also known as E4bp4) and Tbx21 transcription factors. However, mice lacking Il-15 ra-l-did not show this defect (8) . Thus, these intraepithelial NKp46+NK 1.1+CD160+ ILC I cells are distinct from conventional NK cells. The number of these transepithelial group I ILCs was found to be increased in anti-CD40-induced mOUSe models of colitis and secreted higher levels of IFN-y causing severe inflammatory tissue damage. Thus, these group I ILCs may playa protective role against enteropathogens but have a tendency to aggravate inflammatory bowel disease (IBD)/Crohn's disease ( Fig. 1 ). Additionally, these transepithelia1 group I NKp44+ CDI03+ ILCI also express T-bet and Eomes transcription factors along with higher levels of IKZF3 transcript as compared to other ILCs. However, it is not possible to discuss every aspect ofILCs in this manuscript so their major types receptor expression, major cytokines secreted by them and major role played by them are represented in Table I .
Il.Cs in chronic respiratory tract inflammatory disorders (i.e. Asthma)
Asthma is a chronic inflammatory disorder oflower respiratory tract and is characterized by the presence of chronic lung inflammation, infiltration of lungs with mast cells and eosinophils, hypersecretion ofthe mucus, difficulty in breathing (bronchoconstriction). According to one estimate, more than 300 million people are affected with asthma throughout the world (9) . Various studies have shown that symptoms of allergic asthma and lung inflammation develop due to hyper activation of innate lymphoid cells, as activation of these cells led to initiation of type-2 immune response in respiratory tract (10) (11) (12) . These type 2 innate lymphoid cells (ILC2) in lungs express ICaS (CD278), ST2, CD25 and CD44, which require Id2 and CD127 (IL-7Ra) for their development. Pathogenesis of fungal (i.e. Alternaria alternate) aeroallergen induced allergic asthma is also dependent on ILC2 cells. Additionally, mouse model of papain induced pulmonary inflammation also showed that the majority of Th2 cytokines (i.e. IL-4, IL-5, IL-9 and IL-13) were produced by ILCs despite the presence of fully developed Th2 cells. IL-9 produced by ILCs also acts in a paracrine manner and upregulates IL-5 and IL-13 production by these cells (14) . ILCs also play an important role in Strongyloides venezuelensis infection-induced lung eosinophilic inflammation (13) . Infection with S. venezuelensis or intranasal administration of chitin leads to an increase in number of alveolar epithelial type II cells (ATII cells) and IL-33 levels (13) . S. venezuelensis infection induces pulmonary accumulation of ILCs (13) . Increased level of IL-33 stimulates ILCs to produce higher levels of IL-5 and IL-13. This similar effect was also observed in Rag2<-I-l mice, where infection with S. venezuelensis increased the number ofATII cells, ILCs, eosinophils and expression of IL-33 in lungs of infected mice. This IL-33-mediated stimulation ofILCs in lungs led to induction of eosinophilic pulmonary inflammation and helped in the expulsion of worms from lungs. Similar findings have also been observed by Kamijo et al. in protease allergen-associated allergic pulmonary airway inflammation (14) .
Recently, Kim et al. observed that obesityassociated development of asthma is facilitated by NLRP3 inflammasomes, IL-l p and IL-17
producing ILCs (15) . These workers found that airway hyperactivity associated with obesity was also linked to an expansion of CCR6+ type 3 ILCs producing IL-17A (ILC3 cells) in the lung. These authors also found that a high fat diet (HFD) led to release of IL-l p via stimulation of pulmonary alveolar macrophages, which led to an expansion of the number of pulmonary ILC3 cells. Blockade of IL-l p with an IL-l receptor antagonist diminished obesity-induced airway hyper reactivity (AHR) and reduced the number ofILC3 cells. Thus, obesity may be another factor for the exaggerated stimulation of ILC3 cells and development of obesity-related asthma.
IL-33-mediated stimulation ofILC2 cells involves mTOR activation through p l l Od phosphoinositide 3-kinase (16) . Blockade of mTOR pathway inhibited IL-33-induced IL-5 and IL-13 production by both Th2 cells and ILC2s (16) . Intranasal administration of IL-33 induced airway inflammation in WT mice, and adoptive transfer ofwild-type ILCs to IL-33 receptordeficient (St2- 1 -) mice recapitulated this inflammatory and allergic immune response (16) . However, rapamycin (i.e. an mTOR inhibitor) treatment led to inhibition of IL-33-dependent ILC, macrophage, and eosinophil accumulation, cytokine secretion, and exaggerated mucus secretion and its deposition in airways. Hence, this study revealed an unrecognized role of mTOR signaling in IL-33-stimulated, ILCdependent allergic airway inflammation in vivo, which can be used as future therapeutic approach for allergic airway inflammation.
Recently, presence ofNK as well as ILC2 cells in the human lungs and peripheral blood ofboth healthy subjects and patients suffering from asthma has been identified (17) . Pro-resolving ALXlFPR2 receptors are expressed on both NK and ILC2 cells. Lipoxin A 4 (a natural pro-resolving ligand for ALXlFPR2) induced an increased eosinophil apoptosis through the activation ofNK cells and decreased production of IL-13 from ILCs cells (17) . Thus, inhibition of activation of ILC2 via Lipoxin A 4 and ALX/FPR2 receptors may prove beneficial in human cases of asthma. Lower levels of Lipoxin A 4 have been observed in patients with severe asthma, which may be the one of the several reasons for exaggerated activation of ILC2 cells in this group of patients. ILC22 cells secreting IL-22 in lungs exert an antiinflammatory effect during experimental allergic asthma and inhibit acute hypersensitivity reaction (AHR) and pulmonary inflammation. Besides in asthma, group 2 ILCs also play a significant role in the pathogenesis of chronic rhinosinusitis (CRS) by releasing IL-13 in response to IL-33 released through nasal epithelial cells (18) . CRS is a chronic inflammatory condition of the nasal and paranasal sinus mucosa affecting more than 30 million people annually (18) .
ILCs in acute lung infection-associated pulmonary inflammation
ILCs play an important role in influenza virus infection of respiratory tract (19, 20) . Chang et al. showed that influenza A virus infection in mice led to exaggerated production of IL-33 from alveolar macrophages due to hyper activation of ILC2 cells via release of higher amounts of IL-13 (19) , whereas, Monticelli et al. showed that mouse ILCs accumulated in lungs after influenza virus infection, and their depletion led to loss of airway epithelial integrity, diminished lung function and impaired airway remodeling (20) . However, administration of amphiregulin (Arg) (a secretory product oflung ILC2 cells) abrogated these defects and led to restoration of normal lung function and epithelial repair. Thus, lung ILCs exhibit great potential in restoration of airway epithelial integrity and tissue homeostasis after infection with influenza virus (Fig. 2) . These studies show that ILCs play a very important role in chronic as well as acute pulmonary inflammation observed during allergic asthma and acute viral infections. However, their role in acute bacterial infection, such as pneumonia or other chronic inflammatory conditions of lungs like pulmonary fibrosis or emphysema, remains to be defined.
ILCs, intestinal immune defense and inflammation
ILCs are present throughout the intestine and play an important role in homeostasis of mucosal immunity at intestinal mucosal barrier. For example, cryptopatches (CPs) and isolated lymphoid follicles (ILFs) are completely absent in mice which lack NK.22 and LTi/LTi like cells due to absence of aryl hydrocarbon receptor (Ahr, a transcription factor). CPs are mucosal lymphoid organs of intestine present in mice but are absent in human intestine, which contain DCs common lymphoid progenitor (Linckit'Il.Yku') cells, LTi-like cells as well as small number of NKp46+ NK22 cells. Complete absence of RORyt leads to severe loss of ILCs, causing complete loss of all types of gut-associated lymphoid tissues (GALT). Thus, ILCs are important for normal homeostasis of mucosal immune system of the intestine. Accumulation of human type 1 ILCs (which secrete IFN-y) has been observed in inflamed intestine of patients suffering from Crohn's disease (CD) (21) . Additionally, ILCs are also involved in the generation of tertiary lymphoid tissue or organ (TLT or TLO) in intestine under inflammatory conditions. ILCs also play an important role in clearance of intestinal parasites [i.e. Nipostringylus brasiliensis (N brasiliensis)] (22) (Fig. 2) . IL-25-1 -mice exhibited inefficient immune response required to clear N brasiliensis and delayed cytokine production by Th2 cells (23) . IL-25 plays an important role in regulation and activation of non-B/non-T (NBNT), c-kit", FcepsilonRl-cells (NBNTc-Kit+IL-13+ cells), which secrete various specific cytokines (i.e. IL-4-, IL-5-, IL-13) (23). These cytokines are required for regulation of Th2 differentiation, eosinophilia, mastocytosis and hyperplasia of intestinal goblet cells during helminth infection and their expulsion.
This newly identified cell population was originally called 'nuocytes' reflecting their role as primary cells required for IL-13 production (Nu is the 13 th letter of Greek alphabet). IL-25-1 -animals are deficient in 'nuocytes', which well correlates with inefficient expulsion or clearance of N brasiliensis by these animals. Administration of recombinant IL-25 facilitates appearance and activation of NBNTc-kit+IL-13+ cells (Nuocytes), leading to the rapid removal of parasites (23) . This increase in number of nuocytes leading to their expansion can easily be observed in spleen, mesenteric lymph nodes, peritoneal cavity, lungs and blood upon IL-25 cytokine immune challenge. These nuocytes can be identified by expression of different cell surface receptors (i.e. ICOS, Thy1.2, CCR9, IL-7Ra, IL-17BR (IL-25BR), Tl/ST2 (IL-33R) and IL-2Ry (CD 132). In addition to these receptors, nuocytes also express low levels of CCL3 (MIP-la), which provides an answer for observed neutrophilia in mice treated with recombinant IL-25 (rIL-25). In the presence of both IL-17 and IL-33 these nuocytes rapidly proliferate and maintain their healthy state for up to 6 days in vitro, thus both IL-17 and IL-33 are required for proper function of these nuocytes. However, in the presence of IL-33 these cells also produce IL-6, IL-IO and GM-CSF cytokines along with IL-5 and IL-13.
These ILCs also play an important role in immune defense against intestinal bacterial infection. For example, RORyt+ ILCs play an important role in defense against Citrobacter rodentium (24, 25) . During Citrobacter rodentium infection CD4+ LTi cells act as dominant source of early IL-22 release and this response is dependent on IL-23 as ablation of IL-23 impairs the innate immunity (25) . Additionally, depletion of CD4+ LTi cells abrogates infection-induced expression of IL-22 and antimicrobial peptides (AMPs), causing an increase in mortality of infected animals. LTi cells are important for host to provide full protective immunity against bacterial infection (Fig. 2 ). This early release of IL-22 by intestinal ILCs is induced by lymphotoxin (LT) during Citrobacter rodentium infection (25) . Besides playing an important role in bacterial infection these cells are also important for symbiotic bacteria residing at mucosal surfaces (26) .
ILCs regulate selective containment oflymphoidresident bacteria to prevent systemic inflammation associated with chronic diseases (27) . Depletion of intestinal IL-22-producing ILCs caused peripheral dissemination of commensal gut bacteria and initiated the systemic inflammatory response or sepsis (27) (Fig. 2) . Administration of IL-22 led to inhibition of this severe systemic inflammation and V.KUMAR Choroidal neovascularization (C ) and associated inflammation mediated by IL-I?
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Fig. 2. Role ofILCs in different inflammatory conditions ofrespiratory tract (i.e. lungs, upper respiratory tract), intestine and skin barrier. For example. parasitic infections, or bacterial infections or viral infection (i.e. influenza virus infection of lungs) as well as allergens (i.e. MC903) lead to activation of Th2 immune response activation via the activation of group 2 ILCs present in lungs, nasal epithelium, intestine and skin, causing associated inflammatory disorders. Release ofTSLPfrom skin epithelial cells causes activation ofILC2 cells, which causes exaggerated skin inflammation and atopic dermatitis-like conditions. and ILCs play an important role in psoriasiform plaque formation.
peripheral dissemination of bacteria. According to these authors, these disseminating bacteria belong to Alcaligenes species, which originate from host lymphoid tissues. These Alcaligenes were sufficient to promote systemic inflammation in mice depleted of ILCs. Alcaligenes-specific systemic immune response was associated with CD and progressive hepatitis C virus infection in patients as presence of Alcaligenes-specific antibody in serum of patients suffering from CD and chronically hepatitis-C virus infected individuals was confirmed (27) . Mice deficient in RORyt+ ILCs develop severe form of dextran sodium sulphate (DSS)-induced colitis with severe systemic dissemination ofcommensal bacteria and inflammation is mediated by IgG antibody leading to development of systemic inflammation, while WT mice exhibit only colon specific contained colitis without any systemic inflammation . IL-22 produced by ILCs in intestine has protective action against IBD and provides host defense against pathogens (28) . Thus, identification ofILC-mediated pathway for limiting and controlling the containment and prevention of dissemination of Alcaligenes can prove beneficial in terms of designing new therapeutic approach targeting ILCs to limit the systemic inflammation associated with this bacteria during various pathologic conditions (i.e. AIDS, CD, HCV associated hepatitis, Cystic fibrosis (CF) and Cancer etc.). ILC17 restricted to mucosal tissues were significantly lost in the jejunum during simian immunodeficiency virus (SIV) infection (29) . These results indicate that loss of innate immune function mediated by ILC17 cells at mucosal surfaces may lead to disruption of intestinal mucosal immune system integrity and progression of HIV infection in humans or SIV infection in macaques.
Recent findings have shown that both bacteriainduced colitis and colon cancer are accompanied by accumulation of IL-17+IL-22+ colonic innate lymphoid cells (cILCs), and depletion of these cells from colon in mice leads to blockage of development of invasive colonic cancer (30) . Guo et al. identified that STAT3 inhibition during cancer chemotherapy, inhibits production of IL-22 by ILC3 cells and makes host more prone to develop bacterial infection (i.e. Citrobatcer rodentium in mice), diarrhea and associated mortality (31). Citrobacter rodentium is a natural mouse extracellular enteric pathogen that mimics human enterohaemorrhagic E. coli and enteropathogenic E. coli, which are responsible for major causes of diarrheal diseases associated with several thousand deaths of individuals worldwide every year. These authors observed that administration of IL-22 was sufficient to rescue the STAT3 deficient animals from developing severe intestinal bacterial infection, associated diarrhea and mortality. A recent study by Spencer et al. has shown that vitamin A deficiency led to severe deficiency of group 3 ILCs in intestine and upregulated the frequency of number of group 2 ILC populations (32). This further decreased the level of IL-17 and IL-22 production but increased the production ofIL-4, IL-5 and IL-13 (32). Further inhibition of vitamin A signaling by vitamin A metabolite retinoic acid also caused decrease in the number of ILC3s and an increase in the number of ILC2 cells in both wild type (WT) and immunocompromised mice. Thus, retinoic acid controlled the balance of these two ILC subsets in mouse intestine. These vitamin A-deficient mice were more prone to develop bacterial infection (i.e. Citrobacter rodentium) due to deficiency of ILC3s in their intestine. Both vitamin A-deficient , and retinoic acid inhibitor-treated mice exhibited enhanced protection against infection with Trichuris muris. This enhanced protection was supposed to be associated with an increased frequency of IL-13producing ILC2s and was independent of adaptive immunity. Furthermore, as type 2 immunity is associated with tissue repair and increased mucus production, this may improve intestinal mucosal barrier integrity.
lLCs at mucosal, skin barriers and associated inflammatory disorders and regeneration .
Sterile inflammation resulting in the absence of infection due to metabolic or exogenous sources induced stimulation of innate immune system also proves detrimental to host. These ILCs have also been implicated in the initiation of psoriasiform plaque formation in mice and gut microbial associated intestinal inflammation (33, 34). Kim et al. identified the presence of group 2 ILCs in human skin of healthy individuals and found the number of these cells increases in the skin lesions of persons suffering from atopic dermatitis (35). These workers also found the presence of these cells in mouse skin and that they played an important role in the development of atopic dermatitis-like skin disease in these animals. However, according to them, group 2 ILCs present in skin and skin draining lymph nodes play an inflammatory role independent of IL-33 and IL-25-mediated cytokine signaling required for intestinal and pulmonary group 2 ILCs. Instead, their inflammatory role in skin lesions of atopic dermatitis patients was dependent on thymic stromal lymphopoietin (TSLP). A recent study also confirmed this finding and showed that ILC2 cells are present in mouse skin and promote atopic-dermatitis (AD)-like inflammatory immune response (36). LTi cells also play an important role in regeneration of thymus insulted by endogenous cytokine, IL-23. Regeneration ofthymus was induced by upregulation of LTi function through IL-22 administration (37). Thus, ILCs also play an important role in resolution of sterile inflammation and regeneration.
lLCs in oral mucosal barrier infections and various other mucosal sites
Additionally, a recent study showed that during Candida albicans infection, ILC17 play an important role in the control of fungal infection (38). In mouse model of oropharyngeal candidiasis, IL-17A and IL-17F (both cytokines are important for pathogen clearance) are produced promptly during the course of infection in an IL-23-dependent manner. ILCs in oral mucosa are the main source for these cytokines as Ab-mediated depletion ofILCs in RAG l-deficient mice or ILC deficiency in retinoic acid-related orphan receptor c(-/-) mice led to complete failure of control of Candida albicans infection (38). Thus, IL-17-secreting ILCs (i.e. ILC 17) play an important role in host defense against fungal infection at mucosal surfaces. However, ILC 17 in mice lack expression of NCR NKp46 and also are CD4'CD 117', indicating that these ILC 17 are different from NKp46+ ILC22 or IL-22 producing cells or CD4+CD117+ LTi cells.
Furthermore, a role of Thy-l + ILCs has also been identified during choroidal neovascularization (CNV), which is the hallmark of wet age-related macular degeneration (AMD) (39). AMD is the leading cause of irreversible visual damage observed in patients 60 years of age or over in the Western world. During their study, the authors found that IL-17 had a great potential for inducing neovascularization in a vascular endothelial growth factor (VEGF)independent manner in laser-induced experimental CNV in mice. yoT cells and Thy-l +ILCs were the major source of pro-inflammatory cytokine IL-17 in injured eyes causing the development of CNY. Thus, ILCs are emerging as major immune cells playing a role in the pathogenesis of inflammatory damage at different mucosal surfaces (i.e. RT, GIT, nasal mucosal tissues, skin and oral mucosa etc.). In a recent study Mair and Becher found increased infiltration of Thy-l "Sea1+ ILCs in the mouse model of autoimmune CNS inflammation [i.e. Experimental autoimmune encephalitis (EAE)] (40). These Thy-l 'Scal ' ILCs were characterized by the expression of IL-7 receptor and secretion of IL-17 and IFN-y. However, upon specific depletion of this cell population in mice these workers found that infiltration of these Thy-l "Sea I+ ILCs into the CNS did not have any impact on the course of autoimmune CNS inflammation (i.e. EAE) in their mouse model. Thus, further studies focused on ILCs and pathogenesis of brain inflammation are required to establish their active role in inflammatory brain disorders.
Future perspective
These ILCs are relatively newer immunological cells and their function in terms ofintestinal lymphoid tissue generation, and tissue remodeling as well as their pathogenic contribution to different human inflammatory disorders (i.e. CD or inflammatory bowel diseases (IBD), colon cancer, lung Cancer etc.) needs to be studied in detail. A recent study by Kruglov et Amphiregulin (Areg), a secretory product of lung ILC2 has been reported to restore normal lung function and epithelial repair during influenza virus infection-associated pulmonary inflammation. Future. studies to identify the role of Areg during IBD or CD may prove beneficial to restore intestinal epithelial cell integrity and normal intestinal function in patients suffering from intestinal inflammatory disorder. Since Th2 immune response is also associated with llergic immune responses and both ILC2 cells and Th2 cells require GATA3 for their growth, development and function, an interaction between these two cells types during pathogenesis of type 2 allergic immune responses associated with asthma or parasitic infection may prove beneficial to understand the exact pathophysiology of these diseases. For example, it has been observed that ILC2 cells produce more IL-5 and IL-13 upon stimulation with IL-33 in combination with IL-2, IL-7 or TSLP as compared to Th2 cells. Based on current available data, ILC2 cells function at a very early phase of immune response during type 2 allergic immune response (i.e. asthma or during parasitic infection) when naive CD4 T cells differentiate into Th2 cells or ILC2 cells have tendency to synergize the effector or pathogenic memory Th2 cells to induce or exaggerate the inflammatory process. Hence, it has become very important to define phenotypic and functional differences between pathogenic memory Th2 cells and IL-5 and IL-13 producing group 2 ILCs and their impact on type 2 allergic inflammatory disorders. Future studies targeting different approaches towards mechanism of infiltration of different ILCs at the site of mucosal inflammation and their interaction with different innate (i.e. neutrophils, macrophages, mast cells etc.) and adaptive immune cells [various kinds of T cells (i.e. cytotoxic T cells, helper T cells and regulatory T cells etc.) and B cells] will prove beneficial in designing a new therapeutic approach to inflammatory disorders of mucosal tissues.
